This statistic displays the number of alcoholic liver disease related deaths in England in 2021, by gender and age. The number of deaths from alcoholic liver disease was significantly higher among men than women. In 2021, 678 men and 401 women aged between 55 and 59 years old died from alcoholic liver disease.

This statistic shows the death rate from liver cirrhosis in the U.S. in 2019, by age. According to the data, during that time the highest death rate was 37.9 per 100,000 and was among those aged 75-84 years.

Legacy unique identifier: P00205

In 2023, the death rate due to alcohol-related liver cirrhosis among those aged 45-54 years was **** per 100,000. This statistic shows the rate of alcohol-related liver cirrhosis deaths in the U.S. in 2023, by age.

Years of life lost due to mortality from chronic liver disease including cirrhosis (ICD-10 K70, K73-K74). Years of life lost (YLL) is a measure of premature mortality. Its primary purpose is to compare the relative importance of different causes of premature death within a particular population and it can therefore be used by health planners to define priorities for the prevention of such deaths. It can also be used to compare the premature mortality experience of different populations for a particular cause of death. The concept of years of life lost is to estimate the length of time a person would have lived had they not died prematurely. By inherently including the age at which the death occurs, rather than just the fact of its occurrence, the calculation is an attempt to better quantify the burden, or impact, on society from the specified cause of mortality. Legacy unique identifier: P00326

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

In 2024, California had the highest number of liver transplants performed among all U.S. states. That year, there were around 1,243 liver transplants performed in California. The state with the second-highest number of liver transplants was Texas. Liver transplants are the second most common transplant in the United States, behind kidney transplants. Liver transplants in the United States In 2023, there were just over 10,660 liver transplants carried out in the United States. Most liver transplants in the U.S. are among adults aged 50 to 64 years, with this age group accounting for around 43 percent of all liver transplants. The current need for liver transplants exceeds availability, with over nine thousand people in the United States waiting to receive a liver transplant. Liver transplantation is a treatment option for those suffering from end-stage chronic liver disease, in which the liver is damaged beyond repair. Liver disease End-stage chronic liver disease, or liver failure, has various causes including cirrhosis, hepatitis B and C, and liver cancer. Around half of all deaths in the United States caused by liver cirrhosis are related to alcohol use. Liver cirrhosis is scarring of the liver because of long-term damage. The death rate due to alcohol-related cirrhosis in the United States has increased over the past couple decades. Men are much more likely to die from liver cirrhosis than women.

0.1i - Healthy life expectancy at birth0.1ii - Life Expectancy at 650.1ii - Life Expectancy at birth0.2i - Slope index of inequality in life expectancy at birth based on national deprivation deciles within England0.2ii - Number of upper tier local authorities for which the local slope index of inequality in life expectancy (as defined in 0.2iii) has decreased0.2iii - Slope index of inequality in life expectancy at birth within English local authorities, based on local deprivation deciles within each area0.2iv - Gap in life expectancy at birth between each local authority and England as a whole0.2v - Slope index of inequality in healthy life expectancy at birth based on national deprivation deciles within England0.2vii - Slope index of inequality in life expectancy at birth within English regions, based on regional deprivation deciles within each area1.01i - Children in poverty (all dependent children under 20)1.01ii - Children in poverty (under 16s)1.02i - School Readiness: The percentage of children achieving a good level of development at the end of reception1.02i - School Readiness: The percentage of children with free school meal status achieving a good level of development at the end of reception1.02ii - School Readiness: The percentage of Year 1 pupils achieving the expected level in the phonics screening check1.02ii - School Readiness: The percentage of Year 1 pupils with free school meal status achieving the expected level in the phonics screening check1.03 - Pupil absence1.04 - First time entrants to the youth justice system1.05 - 16-18 year olds not in education employment or training1.06i - Adults with a learning disability who live in stable and appropriate accommodation1.06ii - % of adults in contact with secondary mental health services who live in stable and appropriate accommodation1.07 - People in prison who have a mental illness or a significant mental illness1.08i - Gap in the employment rate between those with a long-term health condition and the overall employment rate1.08ii - Gap in the employment rate between those with a learning disability and the overall employment rate1.08iii - Gap in the employment rate for those in contact with secondary mental health services and the overall employment rate1.09i - Sickness absence - The percentage of employees who had at least one day off in the previous week1.09ii - Sickness absence - The percent of working days lost due to sickness absence1.10 - Killed and seriously injured (KSI) casualties on England's roads1.11 - Domestic Abuse1.12i - Violent crime (including sexual violence) - hospital admissions for violence1.12ii - Violent crime (including sexual violence) - violence offences per 1,000 population1.12iii- Violent crime (including sexual violence) - Rate of sexual offences per 1,000 population1.13i - Re-offending levels - percentage of offenders who re-offend1.13ii - Re-offending levels - average number of re-offences per offender1.14i - The rate of complaints about noise1.14ii - The percentage of the population exposed to road, rail and air transport noise of 65dB(A) or more, during the daytime1.14iii - The percentage of the population exposed to road, rail and air transport noise of 55 dB(A) or more during the night-time1.15i - Statutory homelessness - homelessness acceptances1.15ii - Statutory homelessness - households in temporary accommodation1.16 - Utilisation of outdoor space for exercise/health reasons1.17 - Fuel Poverty1.18i - Social Isolation: % of adult social care users who have as much social contact as they would like1.18ii - Social Isolation: % of adult carers who have as much social contact as they would like1.19i - Older people's perception of community safety - safe in local area during the day1.19ii - Older people's perception of community safety - safe in local area after dark1.19iii - Older people's perception of community safety - safe in own home at night2.01 - Low birth weight of term babies2.02i - Breastfeeding - Breastfeeding initiation2.02ii - Breastfeeding - Breastfeeding prevalence at 6-8 weeks after birth2.03 - Smoking status at time of delivery2.04 - Under 18 conceptions2.04 - Under 18 conceptions: conceptions in those aged under 162.06i - Excess weight in 4-5 and 10-11 year olds - 4-5 year olds2.06ii - Excess weight in 4-5 and 10-11 year olds - 10-11 year olds2.07i - Hospital admissions caused by unintentional and deliberate injuries in children (aged 0-14 years)2.07i - Hospital admissions caused by unintentional and deliberate injuries in children (aged 0-4 years)2.07ii - Hospital admissions caused by unintentional and deliberate injuries in young people (aged 15-24)2.08 - Emotional well-being of looked after children2.09i - Smoking prevalence at age 15 - current smokers (WAY survey)2.09ii - Smoking prevalence at age 15 - regular smokers (WAY survey)2.09iii - Smoking prevalence at age 15 - occasional smokers (WAY survey)2.09iv - Smoking prevalence at age 15 years - regular smokers (SDD survey)2.09v - Smoking prevalence at age 15 years - occasional smokers (SDD survey)2.12 - Excess Weight in Adults2.13i - Percentage of physically active and inactive adults - active adults2.13ii - Percentage of physically active and inactive adults - inactive adults2.14 - Smoking Prevalence2.14 - Smoking prevalence - routine & manual2.15i - Successful completion of drug treatment - opiate users2.15ii - Successful completion of drug treatment - non-opiate users2.16 - People entering prison with substance dependence issues who are previously not known to community treatment2.17 - Recorded diabetes2.18 - Admission episodes for alcohol-related conditions - narrow definition2.19 - Cancer diagnosed at early stage (Experimental Statistics)2.20i - Cancer screening coverage - breast cancer2.20ii - Cancer screening coverage - cervical cancer2.21i - Antenatal infectious disease screening – HIV coverage2.21iii - Antenatal Sickle Cell and Thalassaemia Screening - coverage2.21iv - Newborn bloodspot screening - coverage2.21v - Newborn Hearing screening - Coverage2.21vii - Access to non-cancer screening programmes - diabetic retinopathy2.21viii - Abdominal Aortic Aneurysm Screening2.22iii - Cumulative % of the eligible population aged 40-74 offered an NHS Health Check2.22iv - Cumulative % of the eligible population aged 40-74 offered an NHS Health Check who received an NHS Health Check2.22v - Cumulative % of the eligible population aged 40-74 who received an NHS Health check2.23i - Self-reported well-being - people with a low satisfaction score2.23ii - Self-reported well-being - people with a low worthwhile score2.23iii - Self-reported well-being - people with a low happiness score2.23iv - Self-reported well-being - people with a high anxiety score2.23v - Average Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) score2.24i - Injuries due to falls in people aged 65 and over2.24ii - Injuries due to falls in people aged 65 and over - aged 65-792.24iii - Injuries due to falls in people aged 65 and over - aged 80+3.01 - Fraction of mortality attributable to particulate air pollution3.02 - Chlamydia detection rate (15-24 year olds)3.02 - Chlamydia detection rate (15-24 year olds)3.03i - Population vaccination coverage - Hepatitis B (1 year old)3.03i - Population vaccination coverage - Hepatitis B (2 years old)3.03iii - Population vaccination coverage - Dtap / IPV / Hib (1 year old)3.03iii - Population vaccination coverage - Dtap / IPV / Hib (2 years old)3.03iv - Population vaccination coverage - MenC3.03ix - Population vaccination coverage - MMR for one dose (5 years old)3.03v - Population vaccination coverage - PCV3.03vi - Population vaccination coverage - Hib / Men C booster (5 years)3.03vi - Population vaccination coverage - Hib / MenC booster (2 years old)3.03vii - Population vaccination coverage - PCV booster3.03viii - Population vaccination coverage - MMR for one dose (2 years old)3.03x - Population vaccination coverage - MMR for two doses (5 years old)3.03xii - Population vaccination coverage - HPV3.03xiii - Population vaccination coverage - PPV3.03xiv - Population vaccination coverage - Flu (aged 65+)3.03xv - Population vaccination coverage - Flu (at risk individuals)3.04 - People presenting with HIV at a late stage of infection3.05i - Treatment completion for TB3.05ii - Incidence of TB3.06 - NHS organisations with a board approved sustainable development management plan3.07 - Comprehensive, agreed inter-agency plans for responding to health protection incidents and emergencies4.01 - Infant mortality4.02 - Tooth decay in children aged 54.03 - Mortality rate from causes considered preventable4.04i - Under 75 mortality rate from all cardiovascular diseases4.04ii - Under 75 mortality rate from cardiovascular diseases considered preventable4.05i - Under 75 mortality rate from cancer4.05ii - Under 75 mortality rate from cancer considered preventable4.06i - Under 75 mortality rate from liver disease4.06ii - Under 75 mortality rate from liver disease considered preventable4.07i - Under 75 mortality rate from respiratory disease4.07ii - Under 75 mortality rate from respiratory disease considered preventable4.08 - Mortality from communicable diseases4.10 - Suicide rate4.11 - Emergency readmissions within 30 days of discharge from hospital4.12i - Preventable sight loss - age related macular degeneration (AMD)4.12ii - Preventable sight loss - glaucoma4.12iii - Preventable sight loss - diabetic eye disease4.12iv - Preventable sight loss - sight loss certifications4.13 - Health related quality of life for older people4.14i - Hip fractures in people aged 65 and over4.14ii - Hip fractures in people aged 65 and over - aged 65-794.14iii - Hip fractures in people aged 65 and over - aged 80+4.15i - Excess Winter Deaths Index (Single year, all ages)4.15ii - Excess Winter Deaths Index (single year, ages 85+)4.15iii - Excess Winter Deaths Index (3 years, all ages)4.15iv - Excess Winter Deaths Index (3 years, ages 85+)4.16 - Estimated diagnosis rate for people

BackgroundDonation after circulatory death (DCD) liver allografts are associated with higher rates of primary non-function (PNF) and ischemic cholangiopathy (IC). Advanced recovery techniques, including thoracoabdominal normothermic regional perfusion (TA-NRP), may improve organ utilization and patient and allograft outcomes. Given the increasing US experience with TA-NRP DCD recovery, we evaluated outcomes of DCD liver allografts transplanted after TA-NRP.MethodsLiver allografts transplanted from DCD donors after TA-NRP were identified from 5/1/2021 to 1/31/2022 across 8 centers. Donor data included demographics, functional warm ischemic time (fWIT), total warm ischemia time (tWIT) and total time on TA-NRP. Recipient data included demographics, model of end stage liver disease (MELD) score, etiology of liver disease, PNF, cold ischemic time (CIT), liver function tests, intensive care unit (ICU) and hospital length of stay (LOS), post-operative transplant related complications.ResultsThe donors' median age was 32 years old and median BMI was 27.4. Median fWIT was 20.5 min; fWIT exceeded 30 min in two donors. Median time to initiation of TA-NRP was 4 min and median time on bypass was 66 min. The median recipient listed MELD and MELD at transplant were 22 and 21, respectively. Median allograft CIT was 292 min. The median length of follow up was 257 days. Median ICU and hospital LOS were 2 and 7 days, respectively. Three recipients required management of anastomotic biliary strictures. No patients demonstrated IC, PNF or required re-transplantation.ConclusionLiver allografts from TA-NRP DCD donors demonstrated good early allograft and recipient outcomes.

Per capita alcohol consumption in the United States has increased in the past couple of decades to reach **** gallons of ethanol per capita in 2021. Beer has accounted for the largest share of the alcohol market in the United States over most of the last decade, but was overtaken by spirits for the first time in 2022. Health risks Constant and excessive alcohol use has been shown to cause many health complications and increase the risk of many diseases. For example, alcohol consumption increases the risk of various types of cancer, cardiovascular disease, and liver disease. From 2017 to 2021, the rate of new alcohol-associated cancers in the United States was around *** per 100,000 population. Liver cirrhosis A common health complication from the abuse of alcohol is liver cirrhosis. Cirrhosis is scarring of the liver from repeated injury. It can cause other health complications such as high blood pressure, bleeding, and infection, and can result in early death if left untreated. In 2019, there were over ****** alcohol-related liver cirrhosis deaths in the United States, almost double the number reported 15 years earlier.

BackgroundThe creatinine-to-cystatin C ratio (CCR) is an emerging marker of muscle mass, which influences the progression of nonalcoholic fatty liver disease (NAFLD). However, the relationship between CCR and long-term all-cause and cardiovascular mortality remains unclear in the US NAFLD population.MethodsThis nationally representative study analyzed data from the National Health and Nutrition Examination Survey (NHANES) 1999–2004, with mortality follow-up through December 31, 2019 via linkage to the National Death Index (NDI). NAFLD was determined using the Fatty Liver Index (FLI), while CCR was calculated as serum creatinine to cystatin C ratio. We employed multivariable Cox proportional hazards models to assess associations between CCR and mortality risk, expressed as hazard ratios (HRs) with 95% confidence intervals (CIs). The analytical approach included Kaplan–Meier survival analysis, restricted cubic spline regression for non-linear relationship assessment, and comprehensive subgroup and sensitivity analyses to evaluate result robustness.ResultsThis study included 3,897 participants with NAFLD (53.34% male, mean age 48.98 years), with 1,174 all-cause deaths and 333 cardiovascular deaths over a median follow-up of 206 months. CCR demonstrated significant inverse associations with both all-cause mortality (adjusted HR 0.83; 95% CI 0.78–0.88; p 

These are peer-reviewed supplementary materials for the article 'Costs associated with nonalcoholic steatohepatitis disease progression in Medicare patients: a retrospective cohort study' published in the Journal of Comparative Effectiveness Research.Supplemental Figure 1: Event sequencing and cohort construction\Supplemental Table 1: Exclusionary disease codesSupplemental Table 2: Disease state diagnosis and procedure codesAim: Non-alcoholic steatohepatitis (NASH), ormetabolic dysfunction-associated steatohepatitis (MASH), is a severe form of non-alcoholic fatty liver disease (NAFLD) ormetabolic dysfunction-associated liver disease (MASLD), that may progress to advanced liver disease. Costs associated with progression are not well characterized. This study sought to quantify costs and healthcare resource utilization (HRU) associated with NASH progression. Methods: Patients were included if diagnosed with NASH (ICD-10: K75.81) in 100% Medicare claims data (2015–2021) who were ≥66 years at index (diagnosis), continuously enrolled in Parts A, B and D for ≥12 months prior to and 6 months following index (unless death) and who had no evidence of other causes of liver disease. Patient-time was categorized into five severity states: non-cirrhotic NASH, compensated cirrhosis (CC), decompensated cirrhosis (DCC), hepatocellular carcinoma (HCC) and liver transplant (LT). Annualized HRU and costs were calculated during the study periods overall and stratified by occurrence and timing of progression. Results: In 14,806 unique patients (n = 12,990 noncirrhotic NASH; 1899 CC; 997 DCC; 209 HCC; 140 LT), mean age and follow-up were 72.2 and 2.8 years, respectively. Average annualized costs increased from baseline following diagnosis, generally scaling with severity: $16,231 to $27,044; $25,122 to $57,705; $40,613 to $181,036; $36,549 to $165,121 and $35,626 to $108,918 in NASH; CC; DCC; HCC; and LT; respectively. Non-cirrhotic NASH and CC patients with progression had higher follow-up spending (1.6x for NASH; 1.7x for CC) than non-progressors (both p < 0.001), 2.8 and 6.1-times higher odds of an inpatient stay and 2.6 and 3.6-times higher odds to be in the top 20% of spenders, respectively, relative to non-progressors (both p < 0.001). Patients progressing within a year had costs 1.4, 1.6, 1.7 and 2.2-times more than year 2, 3, 4 and 5 progressors’ costs, respectively, for noncirrhotic NASH and 1.3, 1.8, 2.0 and 2.2-times more than year 2, 3, 4 and 5 progressors’ costs, respectively, for CC. Conclusion: NASH progression is associated with high costs that increase in more severe disease states. Slower progression is associated with lower costs, suggesting a potential benefit of therapies that may delay or prevent progression.

In 2022, men in England aged between 65 and 74 years consumed on average 21.4 units of alcohol per week, and women in the same age group drank on average 10 units per week. It is recommended that men and women should not regularly exceed fourteen units of alcohol in a week. For example, fourteen units of alcohol is equivalent to six pints of four percent beer. Correlation in hospital admissions In every year since 2007, the number of hospital admissions for alcoholic liver disease has more than doubled in England. Increasing from 38 thousand admissions to over 82 thousand admissions in 2022. In response to the connection between poor health and alcohol consumption, many people who drink alcohol attempt to moderate their alcohol consumption through various methods. Increase of alcohol-related deaths In 2022, there were almost 10 thousand alcohol-related deaths in the UK. Since 1994 the number of alcohol-related deaths in the UK has been increasing. Additionally, the number of deaths among men due to alcohol is consistently higher than in women in the UK in the last 25 years. In the UK, Scotland has the highest death rate due to alcohol among both genders.

BackgroundInfection is a major complication in liver cirrhosis and causes major morbidity and mortality. However, the incidence and mortality related to these conditions in patients infected with hepatitis C virus (HCV) are unclear, as is whether antiviral therapy could change their infection risk.Methods and findingsIn this community-based cohort study, a total of 115,336 adults (mean age 52.2 years; 35.6% men) without cirrhosis participating in the New Taipei City Health Screening in 2005–2008 were classified as having noncirrhotic HCV (NC-HCV) (n = 2,839), noncirrhotic hepatitis B virus (NC-HBV) (n = 8,316), or no HBV or HCV infection (NBNC) (n = 104,181). Participants were followed to their first hospitalization for infection or death after data linkage with the Taiwan National Health Insurance Research Database (NHIRD) and Death Registry. A Cox proportional hazard regression model, adjusted for age, sex, body mass index (BMI), smoking, alcohol consumption, education level, diabetes, renal function, systemic steroids, and history of hospitalization, was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for overall and individual sites of infection and infection-related mortality. The reference group was NBNC participants with normal to mildly elevated alanine aminotransferase (ALT) (

Introduction: Acute liver failure (ALF) is a rare disease that may lead to cerebral edema and death. An increased optic nerve sheath diameter (ONSD) may reflect an early increase in intracranial pressure. We assessed the feasibility and safety of the ONSD measurement and its association with outcomes in patients with ALF. Methods: This was an open-label prospective cohort study including adult patients with ALF admitted to a liver-specialized intensive care unit (ICU) in an academic center between October 2018 and February 2020 (among 24): 20 as intention-to-treat and 17 as per-protocol analyses. The ONSD measurement (primary exposure) used an ultrasound transducer (3 determinations on each eye per patient). The primary outcome was hospital mortality. Results: Among the 20 patients, 11 (55.0%) were females and the mean age was 45 ± 16 years. On the day of ONSD measurement (median 32.4 h post-ICU admission; IQR 19.8–59.8): 8 patients (40.0%) were in a coma, the mean international normalized ratio (INR) was 3.3 ± 1.4, median bilirubin was 12.3 mg/dL (IQR 4.7–24.5), mean ammonia was 163 ± 101 µmol/L, and mean SOFA score was 11 ± 5. The mean bilateral ONSD was 5.6 ± 0.7 mm, with a very good correlation between right and left eyes (Pearson’s r = 0.90). Ten (50.0%) patients were transplanted and 13 (65.0%) patients survived the hospital stay (all with a 2-month extended Glasgow Outcome Scale of 8). The mean ONSD was significantly higher for hospital non-survivors than survivors both in the intention-to-treat (6.2 vs. 5.3 mm; p = 0.004) and per-protocol (6.2 vs. 5.2 mm; p = 0.004) analyses. No adverse effects from ONSD measurements were reported. Conclusions: In patients with ALF, a higher ONSD was associated with higher hospital mortality. ONSD measurement is feasible and safe and may have prognostic value.